Co-Diagnostics (CODX) Stock Statistics & Valuation Metrics

Co-Diagnostics has a market cap or net worth of $9.30M. The enterprise value is $56.70M.

Co-Diagnostics has 33,712,530 shares outstanding. The number of shares has decreased by -2.65% in one year.

Co-Diagnostics’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -69.69%.

The current PE Ratio of Co-Diagnostics is -0.60. Co-Diagnostics’s PEG ratio is 0.04.

In the last 12 months, Co-Diagnostics had revenue of 3.92M and earned -37.64M in profits. Earnings per share was -1.24.

In the last 12 months, operating cash flow was -29.41M and capital expenditures -437.97K, giving a free cash flow of -29.85M billion.

Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Co-Diagnostics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Co-Diagnostics as a current ratio of 4.41, with Debt / Equity ratio of 0.30%

In the past 12 months, Co-Diagnostics has paid 57.37K in taxes.

Co-Diagnostics EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.73.

Co-Diagnostics has $21.48M in cash and marketable securities with $1.93M in debt, giving a net cash position of -$19.55M billion.

Gross margin is 83.98%, with operating margin of -1023.75%, and net profit margin of -961.37%.

The average price target for Co-Diagnostics is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold